Immunotherapy by CAR-T cells, so far reserved for blood cancers, is now established as a credible strategy in the face of solid tumors, long considered inaccessible to this type of treatment. Advanced gastric cancer, particularly aggressive, remains one of the major causes of oncological mortality, with few therapeutic options once standard treatments are exhausted.
Unpublished immunotherapy against solid tumors
CAR-T cell therapies have so far been reserved for blood cancers like leukemia or lymphomas. But for the first time, this type of immunotherapy has been successfully applied to solid tumors, especially in advanced gastric cancer. The treatment in question, called Satri-Cel, is based on a personalized medicine approach. This involves taking T cells directly from the patient. Then they are genetically changed in the laboratory so that they specifically target a protein called Claudin18.2. This molecule is expressed excessively on the surface of certain cancer cells, especially in gastric tumors and those of the gastroesophageal junction.
Once modified, these T cells become able to recognize and attack the tumor cells bearing this target. But while sparing healthy fabrics. They are then reinjected into the body, where they circulate and activate in contact with cancer cells. The choice of Claudin18.2 as a target is strategic. This protein is present in more than 70 % of gastric cancers, but almost absent from normal tissues. This greatly limits the risk of collateral effects. Satri-Cel is therefore a highly specific treatment, designed to measure for each patient from their own immune cells.
A clear improvement in survival and tumor control
The CT041-St-01 clinical trial, led by Professor Lin Shen at the Beijing Cancer Hospital, has evaluated the effectiveness of satri-CEL cell therapy in 156 patients with gastric or gastroesophageal cancer, all in check after at least two treatment lines. This randomized study compared Satri-Cel to a treatment called “the doctor's choice”. It included standard options such as paclitaxel, docetaxel or nivolumab.
The results show a measurable benefit on two essential criteria: overall survival (OS) and unprofessional survival of the disease (PFS). In the total randomized population, patients receiving Satri-Cel survived an average of 7.92 months against 5.49 months for those treated with conventional therapy. This represents a 30 % reduction in the risk of death.
Tumor control is also significantly improved. The PFS-that is to say the time during which the disease does not progress-goes from 1.77 months to 3.25 months. This doubling of the deadline before progression confirms the antitumor effect of Satri-Cel. In patients who have actually received the infusion (MITT population), the effects are even more marked. The survival reached 8.61 months, and the PFS rises to 4.37 months, with a reduction in the risk of increase of 70 %.
According to Dr. Jason Luke (University of Pittsburgh), this data is a strong signal. He declared to Guardian : ” This is a rocking point for the treatment of solid tumors ». For patients in therapeutic impasse, these figures offer a concrete and encrypted perspective of life extension.
A controlled safety profile despite powerful immunotherapy
Recall that CAR-T therapies, by profoundly modifying the immune system, can cause serious side effects. One of the most feared is Cytokine Relearness Syndrome (CRS). It is a massive inflammatory reaction due to the brutal activation of immune cells. This syndrome can cause fever, hypotension, or even organ failures in severe cases. Another potential complication, neurotoxicity syndrome associated with immune effective cells (Icans), can alter the functioning of the nervous system, resulting in confusion, convulsions or coma.
In the study CT041-St-01, these risks were therefore closely monitored. However, the data show that Satri-Cel has a relatively well mastered security profile. Only four cases of grade 3 CRS have been reported (severe form). But no case of grade 4 or 5 has been observed, that is to say no form involving the vital prognosis. In addition, no patient has presented symptoms of neurotoxicity (Icans), a particularly reassuring result.
These elements indicate that the side effects of Satri-Cel remain generally controllable in a suitable medical environment, with surveillance and intervention protocols already well established in oncology. For Dr. John Haanen, Dutch specialist in immunotherapy, this makes this treatment ” finally accessible for oncologists dealing with solid tumors ». Patient safety remains a decisive criterion for any innovative therapy. An acceptable tolerance profile is therefore essential to consider use on a larger scale in clinical practice.
A revolution in the march for patients excluded from conventional treatments
Advanced gastric cancer is among the most difficult forms to treat, due to its aggressiveness and its often late detection. After the failure of chemotherapy and targeted treatments, therapeutic options are very limited, leaving patients without concrete perspective. In this context, the arrival of specific cell immunotherapy, such as Satri-Cel, represents a paradigm shift. It no longer aims only to slow down the disease. But it aims to mobilize the immune system to recognize and eliminate cancer cells actively.
The results obtained in this trial are not only a scientific promise against cancer. This is a very realistic perspective for a group of patients historically neglected by therapeutic research. For Catherine Elliott, director of Research UK cancer research, this advance constitutes “a real signal of hope”, while recalling that a large -scale deployment will require additional trials and longer -term confirmations.
Carsgen already plans to expand the scope of satri-Cel to other tumors expressing the protein Claudin18.2, in particular the cancers of the pancreas, just as resistant and murderous. The objective is to intervene earlier in the trajectory of the disease, and potentially in consolidation treatment after surgery.
Personalized cell immunotherapy therefore enters a new phase. It is no longer limited to blood cancers. It begins to get foot in the very complex field of solid tumors. Satri-Cel may well pave the way for a new generation of treatments. More targeted treatments, better tolerated and accessible to patients today without solution.
Source: qi, Changsong et al., “Claudin-18 Isoform 2-Specific Car T-Cell Therapy (Satri-Cel) Versus Treatment of Physician's Choice for Previously Treated Advanced Gastro-Oesophagal Cancer (CT041-St-01): a randomized, open-label. The Lancet, 2025
With an unwavering passion for local news, Christopher leads our editorial team with integrity and dedication. With over 20 years’ experience, he is the backbone of Wouldsayso, ensuring that we stay true to our mission to inform.
